Study Links Metabolic Syndrome to Degenerative Changes, Not Inflammatory Damage, in Psoriatic Arthritis
A new longitudinal cohort study evaluating over four decades of patient data has found that while metabolic syndrome (MetS) is common in psoriatic arthritis (PsA) and associated with disease activity, it does not correlate with radiographic damage traditionally linked to PsA. Instead, MetS is independently associated with degenerative changes in the spine and entheses.
The study, conducted using a prospective PsA cohort from 1978 to 2024, included 1,422 patients. Of these, 400 (28.1%) had MetS at baseline, and 836 (58.8%) had a record of MetS based on the harmonized definition during a median follow-up of 10.6 years. Researchers used generalized estimating equations (GEE) to assess associations between MetS and radiographic features, adjusting for relevant covariates such as age, sex, disease duration, decade of enrollment, and use of targeted disease-modifying antirheumatic drugs (DMARDs).
The analysis revealed a key finding: MetS was not significantly associated with axial disease or radiographic peripheral joint damage in PsA. Axial disease features assessed included the presence of syndesmophytes and sacroiliitis, while peripheral joint damage was measured using radiographic damaged joint count. These outcomes remained nonsignificant after full adjustment.
“In the GEE analysis, MetS was not significantly associated with axial disease or radiographic damage to peripheral joints,” the authors report. This challenges assumptions that systemic inflammation driven by MetS might exacerbate PsA-associated joint damage.
However, the study did identify a significant association between MetS and degenerative radiographic findings. Specifically, MetS was independently linked to the presence of calcaneal spurs, diffuse idiopathic skeletal hyperostosis (DISH), and degenerative disc disease—findings that are considered markers of mechanical and metabolic stress, rather than autoimmune inflammation.
“MetS was significantly associated with calcaneal spurs, diffuse idiopathic skeletal hyperostosis, and degenerative disc disease,” the authors state. These degenerative changes likely reflect non-inflammatory pathways through which MetS contributes to musculoskeletal morbidity in patients with PsA.
This distinction is clinically important for rheumatologists managing patients with PsA and comorbid MetS. While inflammatory joint damage remains the primary concern in PsA, the presence of MetS may signal a parallel burden of non-inflammatory, degenerative musculoskeletal disease that may not be mitigated by immunomodulatory therapy alone.
The study’s large cohort, long follow-up period, and use of adjusted statistical modeling strengthen the validity of the findings. Clinicians are encouraged to consider both inflammatory and non-inflammatory sources of pain and functional limitation in patients with PsA and MetS, and to tailor management accordingly.
In conclusion, the study underscores a nuanced relationship between MetS and PsA-related radiographic outcomes. “MetS is associated with degenerative and metabolic changes in the spine and entheses but not with radiographic damage in PsA,” the authors conclude. This finding supports the need for comprehensive musculoskeletal assessment in patients with PsA and MetS, beyond the traditional focus on inflammatory joint damage.
Reference
Kharouf F, Gao S, Tunc SE, et al. Association between metabolic syndrome and radiographic changes in psoriatic arthritis: a cohort study. Arthritis Care Res (Hoboken). 2025;77(7):867-872. doi:10.1002/acr.25513
